Search the Newsreel

Lead Real Estate Co Ltd (LRE) Earnings Forecast: Future EPS & Revenue Growth Estimates

Earnings call transcript: WAM Leaders posts strong FY 2026 return, lifts dividend

Leader Education Reschedules Extraordinary General Meeting and Adjusts Shareholder Record Dates

GILD- An Attractive Biotech Stock with Solid Base Revenue Growth

Gilead Sciences Inc. (GILD) just reported June quarter revenue up 10.2% from last year to $7.8 billion, ahead of estimates. Due to an $11.2 billion one-time write-off of acquired in-process R&D, they reported a $6.75 per share pro forma loss. But that was smaller …

WAM Leaders wraps $225m placement, lifts FY26 dividend

Gilead Sciences, Inc. Revenue Breakdown – SIX:GILD

Gilead Sciences, Inc. generated 23.34 billion CHF in revenue last year. Its top-performing segment, Human Immunodeficiency Virus, contributed 16.45 billion CHF, a decrease from the previous year. The United States was the largest regional contributor, accounting for 16.55 billion CHF.

Noticias de acciones de Gilead Sciences Inc (GILD)

Should Gilead’s Swing to a Full‑Year Loss Outlook Require Action From Gilead Sciences (GILD) Investors?

Gilead Sciences recently reported a significant net loss of US$10.50 billion in Q2 2026, alongside cutting its full-year earnings outlook despite higher revenue. This shift to a projected full-year loss raises questions about how the company will balance investment, capital returns, and future financing, …

Gilead Sciences Inc (GILD) Aktuelle Aktien-News

Notícias das Ações da Gilead Sciences Inc (GILD)

Arcus Biosciences (NYSE: RCUS) gets 24.7% ownership from Gilead

Gilead Sciences, Inc. has reported a beneficial ownership of 24.7% in Arcus Biosciences, Inc. (NYSE: RCUS), holding 31,424,760 shares out of 127,333,376 outstanding. This stake was built through multiple equity purchases dating back to 2020 and is linked to an Option, License and Collaboration …

Why Canadian Large Cap Leaders stock is tanking today

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Sciences, Inc. GILD used its second-quarter 2026 call to emphasize stronger base-business growth, led by HIV, PrEP, Trodelvy and Livdelzi, while outlining a busy second-half launch calendar. Non-GAAP loss per share was $6.75, better than the Zacks Consensus Estimate for a loss of …

Czech National Bank Raises Stock Holdings in Gilead Sciences, Inc. $GILD

The Czech National Bank increased its stake in Gilead Sciences (NASDAQ:GILD) by 4.6% in Q2, bringing its total holdings to 353,398 shares valued at $44.6 million. Gilead Sciences reported Q2 revenue of $7.8 billion, exceeding analyst expectations, despite a reported loss due to acquisition …

PensionDanmark Pensionsforsikringsaktieselskab Purchases 25,515 Shares of Gilead Sciences, Inc. $GILD

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.3% in the second quarter, acquiring an additional 25,515 shares and bringing their total holdings to 233,799 shares valued at $29.54 million. This article details various institutional investor activities, recent positive and negative …

NewEdge Advisors LLC Buys 231,715 Shares of Gilead Sciences, Inc. $GILD

NewEdge Advisors LLC significantly increased its stake in Gilead Sciences (NASDAQ:GILD) by 144.2% in the first quarter, purchasing an additional 231,715 shares, bringing their total holdings to 392,435 shares valued at $54.7 million. This move is part of broader institutional investor activity in GILD …

Assenagon Asset Management S.A. Boosts Stock Holdings in Gilead Sciences, Inc. $GILD

Assenagon Asset Management S.A. significantly increased its stake in Gilead Sciences, Inc. by 346.5% in the second quarter, now owning 2,287,888 shares worth $289,052,000. Other institutional investors also adjusted their positions in the biopharmaceutical company. Gilead Sciences reported strong Q2 revenue of $7.8 billion, …

Gilead Sciences (GILD) Could Be Trading At A 20% Discount Following Raised Guidance

Gilead Sciences (NASDAQ: GILD) sets up automatic shelf for wide range of securities

Gilead Sciences has filed an automatic shelf registration statement on Form S-3, enabling it to offer a wide range of securities, including debt, common stock, preferred stock, and warrants, from time to time. This broad filing allows the company flexibility in future fundraising, with …

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics, Inc. KYMR reported a second-quarter 2026 loss of 62 cents per share, narrower than the Zacks Consensus Estimate of a loss of 64 cents. The company posted a loss of 95 cents in the year-ago period. Revenues surged to $65 million from …

Gilead Sciences: A Strong Quarter Hidden Behind A Bottom-Line Loss (NASDAQ:GILD)

Nanjing Leads Biolabs Advances Key Liver Cancer Trial for Opamtistomig

Nanjing Leads Biolabs Advances Liver Cancer Drug to Phase 2 Expansion

Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors

Gilead Sciences Inc. (GILD) stock fell 2.58% to $131.76 on Wednesday, underperforming compared to its competitors and ending a two-day winning streak. This occurred on a mixed trading day where the Dow Jones Industrial Average rose, but the S&P 500 Index declined.

Arcus Biosciences (NYSE: RCUS) posts Q2 loss, ends Gilead options

Arcus Biosciences reported a Q2 2026 net loss of $91 million, or $0.72 per share, with total revenues of $41 million, a significant decrease from $160 million in Q2 2025 due to the absence of a large one-time payment from Gilead. Broad Gilead option …

Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat

Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock slipped, still in a downtrend. Continue Reading

Gilead (GILD) Faces HIV Drug Access Criticism From AIDS Healthcare Foundation

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AIDS Healthcare Foundation publicly criticizes Gilead Sciences on its global HIV drug pricing and access policies. The advocacy group alleges that Gilead benefits from taxpayer-funded research while …

Gilead Sciences Inc Stock (GILD) Moved Down by 3.96% on Aug 5: A Full Analysis

Gilead Sciences Inc (GILD) stock dropped by 3.96% on August 5th following a downward revision of its full-year earnings guidance. This decline is attributed to decelerating sales in its core HIV franchise, disappointing clinical trial results in oncology, and increased operational and research costs. …

Gilead Sciences (GILD) Faces Fresh HIV Access Criticism From AIDS Healthcare Foundation

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AIDS Healthcare Foundation publicly criticizes Gilead Sciences on its global HIV drug pricing and access policies. The advocacy group alleges that Gilead benefits from taxpayer-funded research while …

The Bull Case For Gilead Sciences (GILD) Could Change Following Deeper 2026 Losses Amid HIV, Oncology Growth

In early August 2026, Gilead Sciences reported second-quarter revenue of US$7.80 billion but moved to a quarterly net loss of US$10.50 billion, widened its full-year 2026 loss guidance, and still affirmed a US$0.82 per-share dividend while continuing selective share repurchases. Despite the reported loss …

Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026

Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026 Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 10.2% year on year to $7.80 billion. On the other hand, the company's full-year revenue guidance of …

Gilead Raised HIV Guidance on Its Q2 Earnings Call. Here’s What That Means for GILD Stock.

Gilead Sciences Announces Second Quarter 2026 Financial Results

Gilead Sciences announced its second quarter 2026 financial results, reporting a 10% year-over-year revenue growth in its base business, driven by its HIV portfolio, Trodelvy, and Livdelzi. The company reported diluted loss per share of $(8.45) and non-GAAP diluted loss per share of $(6.75), …

California High Court’s Gilead Ruling Marks Tort Law Sea Change

The California Supreme Court has issued a landmark ruling shielding Gilead Sciences Inc. from liability related to developing and marketing its drugs, even if safer alternatives exist within its pipeline. This decision, described as a "monumental shift," provides an exception from the duty of …

Gilead Sciences Inc (GILD) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Gilead Sciences (GILD) Stock Price Reflects R And D Shock Not Sales Weakness